Abstract:The enteric nervous system (ENS) is contained within two layers of the gut wall and is made up of neurons, immune cells, and enteric glia cells (EGCs) that regulate gastrointestinal (GI) function. EGCs in both inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) change in response to inflammation, referred to as reactive gliosis. Whether EGCs restricted to a specific layer or region within the GI tract alone can influence intestinal immune response is unknown. Using bulk RNA-sequencing and hybridization, we identify G-protein coupled receptor , as a gene expressed only in EGCs of the myenteric plexus, one of the two layers of the ENS. We show that Gpr37 contributes to key components of LPS-induced reactive gliosis including activation of NF-kB and IFN-y signaling and response genes, lymphocyte recruitment, and inflammation-induced GI dysmotility. Targeting Gpr37 in EGCs presents a potential avenue for modifying inflammatory processes in the ENS.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of G - protein - coupled receptor Gpr37 in inflammation - induced gastrointestinal motility disorders, especially by regulating the reactive gliosis of enteric glial cells (EGCs) to influence this process. Specifically, the researchers wanted to understand: 1. **Regional and layer - specific heterogeneity of EGCs**: The researchers first explored whether EGCs exhibit different densities and tissue structures in different regions and layers of the gastrointestinal tract, and whether these differences would affect their functions. 2. **Expression and function of Gpr37 in EGCs**: Through RNA sequencing and in - situ hybridization techniques, the researchers determined that Gpr37 is mainly expressed in EGCs of the myenteric plexus (MP), and this expression is region - specific, that is, the expression in the small intestine is higher than that in the colon. 3. **Role of Gpr37 in the inflammatory response**: The researchers used LPS (lipopolysaccharide) as an inflammatory model to explore the specific role of Gpr37 in the inflammatory response. They found that Gpr37 is involved in key signaling pathways of the inflammatory response, such as the NF - κB and interferon signaling pathways, as well as lymphocyte recruitment. 4. **Effect of Gpr37 deletion on the inflammatory response**: By comparing the performance of wild - type and Gpr37 - knockout mice in LPS - induced inflammatory responses, the researchers found that Gpr37 deletion significantly attenuated LPS - induced EGCs reactive gliosis and the expression of related genes, reduced lymphocyte recruitment, and alleviated inflammation - induced gastrointestinal motility disorders. In summary, the main objective of this paper is to reveal the mechanism of action of Gpr37 in inflammation - induced gastrointestinal motility disorders, especially its role in regulating the reactive gliosis of EGCs, thereby providing new potential targets for the treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Gpr37 modulates the severity of inflammation-induced GI dysmotility by regulating enteric reactive gliosis